Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839996 | 1.00 | CHRNA7 (0.67) | CHRNA7CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3839403 | 0.91 | CHRNA7 (0.65) | CHRNA7CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3839405 | 0.91 | CHRNA7 (0.65) | CHRNA7CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3840559 | 0.86 | CHRNA7 (0.61) | CHRNA7CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3840558 | 0.86 | CHRNA7 (0.61) | CHRNA7CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3844243 | 0.85 | CHRNA7 (0.60) | CHRNA7CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3844247 | 0.85 | CHRNA7 (0.60) | CHRNA7CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL1458614 | 0.83 | CHRNA7 (0.77) | CHRNA7CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL1458612 | 0.83 | CHRNA7 (0.77) | CHRNA7CHRM1CHRM2CHRM4CHRM5 | |
| Aqw051 SCHEMBL29604108 | 0.81 | CHRNA7 (1.00) | CHRNA7CHRM1LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537104-B1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| US-7579362-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists | NOVARTIS AG (CH) | 2009-08-25 | — | — | US | claimed |
| US-11433057-B2 | Method for improving or enhancing cognition | VANDA PHARMACEUTICALS INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200397765-A1 | METHOD FOR IMPROVING OR ENHANCING COGNITION | VANDA PHARMACEUTICALS INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433057-B2 | Method for improving or enhancing cognition | CHAT, GAP43, OTC | CHRNA7 15/4885CHRM1 107/4885CHRM2 31/4885 |
| US-20200397765-A1 | METHOD FOR IMPROVING OR ENHANCING COGNITION | CHAT, GAP43, OTC | CHRNA7 15/4885CHRM1 107/4885CHRM2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.